<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01365676</url>
  </required_header>
  <id_info>
    <org_study_id>GAM+HIP</org_study_id>
    <nct_id>NCT01365676</nct_id>
  </id_info>
  <brief_title>GAMALINE®+HIPERICIN® for PMS Treatment and Vasomotor Symptoms</brief_title>
  <acronym>657/10UFCSPA</acronym>
  <official_title>Phase 3 Study Efficacy and Tolerance: The Use of 2 Phytomedicines in Association GAMALINE® 900mg + HIPERICIN® 300mg for the Treatment of Pre-Menstrual Syndrome (PMS) and Vasomotor Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phytopharm Consulting Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herbarium Laboratório Botânico Ltda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal University of Health Science of Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Phytopharm Consulting Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      2 phytomedicines already in the market: GAMALINE® for premenstrual syndrome and HIPERICIN® as
      antidepressant will be prescribed together for treating women with Premenstrual Syndrome
      (PMS) symptoms and vasomotor problems for checking the advantage compared to the GAMALINE®
      prescription alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Test with 2 female groups: 25-44 years old (reproductive age) and 45-55 years old
      (climacteric premenopausal age) complaining about all symptoms related with premenstrual
      syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PMS calendar</measure>
    <time_frame>240 days</time_frame>
    <description>Evaluation will run daily during the 240 days, comparing the results before treatment [60 days (T-2) and 30 days (T-1)]. Starting point (T0) treatment/under prescription, till 180 days treatment (T6).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LAB Tests</measure>
    <time_frame>T0 T1 and T6</time_frame>
    <description>Blood sample tests before T0 (all arms), after T1 (30 days only for experimental group) and end of T6 (after 180 days of prescription for all arms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WHOQOL</measure>
    <time_frame>06 months</time_frame>
    <description>WHOQOL will be evaluated at T-2 and T6 where T-2 is at the first interview after inclusion and T6 is at the end point of treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Premenstrual Syndrome</condition>
  <condition>Uterus; Hemorrhage, Preclimacteric or Premenopausal</condition>
  <arm_group>
    <arm_group_label>GAMALINE® + HIPERICIN® 25-44 years old</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fertile women 24-44 years old with PMS symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GAMALINE® 25-44 years old</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fertile women 24-44 years old with PMS symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GAMALINE® + HIPERICIN® 45-55 years old</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Climacteric women with PMS symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GAMALINE® 45-55 years old</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Climacteric women with PMS symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GAMALINE® + HIPERICIN®</intervention_name>
    <description>GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)</description>
    <arm_group_label>GAMALINE® + HIPERICIN® 25-44 years old</arm_group_label>
    <arm_group_label>GAMALINE® + HIPERICIN® 45-55 years old</arm_group_label>
    <other_name>GAMALINE® BATCH 8663A0 MS 1.1860.0061.002-9</other_name>
    <other_name>HIPERICIN® BATCH 867911 MS 1.1860.0003.003-0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GAMALINE®</intervention_name>
    <description>GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)</description>
    <arm_group_label>GAMALINE® 25-44 years old</arm_group_label>
    <arm_group_label>GAMALINE® 45-55 years old</arm_group_label>
    <other_name>GAMALINE® BATCH 8663A0 MS 1.1860.0061.002-9</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  fertile women between 25-44 years old

          -  climacteric women between 45-55 years old

        Exclusion Criteria:

          -  inferior age to 25 years old

          -  superior age to 55 years old

          -  post-menopausal

          -  under hormone therapy

          -  thyroid disease

          -  under psychiatric therapy or medication

          -  history for allergies and/or hypersensitivity to any component

          -  breast feeding or pregnancy

          -  no knowledge for writing and/or reading
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla Vanin, MD MSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UFCSPA-Universidade Federal de Ciências da Saúde de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karla F Deud José, PharmD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Phytopharm Consulting Brazil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marli Chaves, Secretary</last_name>
    <phone>+55 51 8130-8454</phone>
    <email>tpm@phytopharm.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gustavo Remus, Physical Education</last_name>
    <phone>+55 51 9191-6535</phone>
    <email>remus@phytopharm.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ambulatório de Ginecologia e Obstetrícia ISCMPA</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marli Chaves</last_name>
      <phone>+55 51 81308454</phone>
      <email>tpm@phytopharm.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Karla F Deud José, PharmD PhD</last_name>
      <phone>+55 51 92793075</phone>
      <email>karla@phytopharm.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Carla Vanin, MD MSc PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raquel P Dibi, MD MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2011</study_first_posted>
  <last_update_submitted>December 5, 2011</last_update_submitted>
  <last_update_submitted_qc>December 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Edema</keyword>
  <keyword>Depression</keyword>
  <keyword>Hot Flashes</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Irritability</keyword>
  <keyword>PMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Premenstrual Syndrome</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

